Secretory phospholipase A2-mediated progression of hepatotoxicity initiated by acetaminophen is exacerbated in the absence of hepatic COX-2

Toxicology and Applied Pharmacology

Volumn 251, Issue 3, 2011, Pages 173-180

  Bhave, Vishakha S ^a   Donthamsetty, Shashikiran ^a   Latendresse, John R ^b   Cunningham, Michael L ^c   Mehendale, Harihara M ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Acetaminophen; Cycloxygenase 2; Hepatotoxicity; Prostaglandin E2; Secretory Phospholipase A2; TNF

Indexed keywords

CYCLOOXYGENASE 2; MEMBRANE PHOSPHOLIPID; PARACETAMOL; PHOSPHOLIPASE A2; TUMOR NECROSIS FACTOR ALPHA; ANALGESIC AGENT; PROSTAGLANDIN E2; SECRETORY PHOSPHOLIPASE A2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME RELEASE; LIVER INJURY; LIVER TOXICITY; MALE; MORTALITY; MOUSE; NONHUMAN; PROTEIN INDUCTION; ANIMAL; BLOOD; ENZYMOLOGY; GENETICS; LIVER REGENERATION; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; SURVIVAL; TIME; TOXIC HEPATITIS;

MUS; RATTUS;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANIMALS; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE PROGRESSION; DRUG-INDUCED LIVER INJURY; LIVER REGENERATION; MALE; MICE; MICE, KNOCKOUT; PHOSPHOLIPASES A2, SECRETORY; SURVIVAL; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952008241     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.01.013     Document Type: Article

References (43)

1. Aspinall R.L., Cammarata P.S. Effect of prostaglandin E2 on adjuvant arthritis. Nature 1969, 224:1320-1321.
2. Barbuio R., Milanski M., Bertolo M.B., Saad M.J., Velloso L.A. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J. Endocrinol. 2007, 194:539-550.
3. Beck S., Lambeau G., Scholz-Pedretti K., Gelb M.H., Janssen M.J., Edwards S.H., Wilton D.C., Pfeilschifter J., Kaszkin M. Potentiation of tumor necrosis factor alpha-induced secreted phospholipase A2 (sPLA2)-IIA expression in mesangial cells by an autocrine loop involving sPLA2 and peroxisome proliferator-activated receptor alpha activation. J. Biol. Chem. 2003, 278:29799-29812.
4. Beraza N., Marques J.M., Martinez-Anso E., Iniguez M., Prieto J., Bustos M. Interplay among cardiotrophin-1, prostaglandins, and vascular endothelial growth factor in rat liver regeneration. Hepatology 2005, 41:460-469.
5. Bhave V.S., Donthamsetty S., Latendresse J.R., Mehendale H.M. Inhibition of cyclooxygenase-2 aggravates secretory phospholipase A2-mediated progression of acute liver injury. Toxicol. Appl. Pharmacol. 2008, 228:239-246.
6. Bhave V.S., Donthamsetty S., Latendresse J.R., Muskhelishvili L., Mehendale H.M. Secretory phospholipase A2 mediates progression of acute liver injury in the absence of sufficient cyclooxygenase-2. Toxicol. Appl. Pharmacol. 2008, 228:225-238.
7. Brune K., Linder J. Increased liver toxicity of diclofenac by paracetamol: results and possible mechanisms. Side-Effects of Anti-Inflammatory Drugs 3 1992, Kluwer Academic Publishers. K.D. Rainsford, G.P. Velo (Eds.).
8. Casado M., Callejas N.A., Rodrigo J., Zhao X., Dey S.K., Bosca L., Martin-Sanz P. Contribution of cyclooxygenase 2 to liver regeneration after partial hepatectomy. FASEB J. 2001, 15:2016-2018.
9. Chanda S., Mehendale H.M. Nutritional impact on the final outcome of liver injury inflicted by model hepatotoxicants: effect of glucose loading. FASEB J. 1995, 9:240-245.
10. Chanda S., Mangipudy R.S., Warbritton A., Bucci T.J., Mehendale H.M. Stimulated hepatic tissue repair underlies heteroprotection by thioacetamide against acetaminophen-induced lethality. Hepatology 1995, 21:477-486.
11. Claria J., Romano M. Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. Curr. Pharm. Des. 2005, 11:3431-3447.
12. Colville-Nash P.R., Gilroy D.W. Cyclooxygenase enzymes as targets for therapeutic intervention in inflammation. Drug News Perspect. 2000, 13(10):587-597.
13. Demeure C.E., Yang L.P., Desjardins C., Raynauld P., Delespesse G. Prostaglandin E2 primes naive T cells for the production of anti-inflammatory cytokines. Eur. J. Immunol. 1997, 27:3526-3531.
14. Donthamsetty S., Bhave V.S., Mitra M.S., Latendresse J.R., Mehendale H.M. Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPAR alpha with clofibrate. Toxicol. Appl. Pharmacol. 2008, 230:327-337.
15. Fernandez-Martinez A., Callejas N.A., Casado M., Bosca L., Martin-Sanz P. Thioacetamide-induced liver regeneration involves the expression of cyclooxygenase 2 and nitric oxide synthase 2 in hepatocytes. J. Hepatol. 2004, 40:963-970.
16. Gilroy D.W., Tomlinson A., Willoughby D.A. Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. Eur. J. Pharmacol. 1998, 355:211-217.
17. Gilroy D.W., Lawrence T., Perretti M., Rossi A.G. Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug Discov. 2004, 3:401-416.
18. Gilroy D.W., Newson J., Sawmynaden P., Willoughby D.A., Croxtall J.D. A novel role for phospholipase A2 isoforms in the checkpoint control of acute inflammation. FASEB J. 2004, 18:489-498.
19. Horrillo R., Planaguma A., Gonzalez-Periz A., Ferre N., Titos E., Miquel R., Lopez-Parra M., Masferrer J.L., Arroyo V., Claria J. Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor. J. Pharmacol. Exp. Ther. 2007, 323:778-786.
20. Hortelano S., Zeini M., Casado M., Martin-Sanz P., Bosca L. Animal models for the study of liver regeneration: role of nitric oxide and prostaglandins. Front. Biosci. 2007, 12:13-21.
21. Ishida Y., Kondo T., Tsuneyama K., Lu P., Takayasu T., Mukaida N. The pathogenic roles of tumor necrosis factor receptor p55 in acetaminophen-induced liver injury in mice. J. Leukoc. Biol. 2004, 75:59-67.
22. Jäättelä M. Overexpression of major heat shock protein hsp70 inhibits tumor necrosis factor-induced activation of phospholipase A2. J. Immunol. 1993, 151:4286-4294.
23. Jollow D.J., Mitchell J.R., Potter W.Z., Davis D.C., Gillette J.R., Brodie B.B. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J. Pharmacol. Exp. Ther. 1973, 187:195-202.
24. Kawabata K., Fujioka D., Kobayashi T., Saito Y., Obata J.E., Nakamura T., Yano T., Watanabe K., Watanabe Y., Mishina H., Kugiyama K. Inhibition of secretory phospholipase A2 activity attenuates acute cardiogenic pulmonary edema induced by isoproterenol infusion in mice after myocardial infarction. J. Cardiovasc. Pharmacol. 2010, 56:369-378.
25. Lappas M., Permezel M., Rice G.E. 15-Deoxy-Delta(12, 14)-prostaglandin J(2) and troglitazone regulation of the release of phospholipid metabolites, inflammatory cytokines and proteases from human gestational tissues. Placenta 2006, 27:1060-1072.
26. Larson A.M., Polson J., Fontana R.J., Davern T.J., Lalani E., Hynan L.S., Reisch J.S., Schiodt F.V., Ostapowicz G., Shakil A.O., Lee W.M. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005, 42:1364-1372.
27. Limaye P.B., Apte U.M., Shankar K., Bucci T.J., Warbritton A., Mehendale H.M. Calpain released from dying hepatocytes mediates progression of acute liver injury induced by model hepatotoxicants. Toxicol. Appl. Pharmacol. 2003, 191:211-226.
28. Limaye P.B., Bhave V.S., Palkar P.S., Apte U.M., Sawant S.P., Yu S., Latendresse J.R., Reddy J.K., Mehendale H.M. Upregulation of calpastatin in regenerating and developing rat liver: role in resistance against hepatotoxicity. Hepatology 2006, 379-388.
29. Malleo G., Mazzon E., Siriwardena A.K., Cuzzocrea S. Role of tumor necrosis factor-alpha in acute pancreatitis: from biological basis to clinical evidence. Shock 2007, 28:130-140.
30. Mehendale H.M. Role of hepatocellular regeneration and hepatolobular healing in the final outcome of liver injury. A two-stage model of toxicity. Biochem. Pharmacol. 1991, 42:1155-1162.
31. Mehendale H.M. Role of tissue repair in liver injury. Drug-Induced Liver Disease 2007, Informa Healthcare, Philadelphia. N. Kaplowitz, L. DeLeve (Eds.).
32. Menschikowski M., Hagelgans A., Siegert G. Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?. Prostaglandins Other Lipid Mediat. 2006, 79:1-33.
33. Napirei M., Basnakian A.G., Apostolov E.O., Mannherz H.G. Deoxyribonuclease 1 aggravates acetaminophen-induced liver necrosis in male CD-1 mice. Hepatology 2006, 43:297-305.
34. Oppenheimer-Marks N., Kavanaugh A.F., Lipsky P.E. Inhibition of the transendothelial migration of human T lymphocytes by prostaglandin E2. J. Immunol. 1994, 152:5703-5713.
35. Piraino G., Cook J.A., O'Connor M., Hake P.W., Burroughs T.J., Teti D., Zingarelli B. Synergistic effect of peroxisome proliferator activated receptor-gamma and liver X receptor-alpha in the regulation of inflammation in macrophages. Shock 2006, 26:146-153.
36. Quiroga J., Prieto J. Liver cytoprotection by prostaglandins. Pharmacol. Ther. 1993, 58:67-91.
37. Reilly T.P., Brady J.N., Marchick M.R., Bourdi M., George J.W., Radonovich M.F., Pise-Masison C.A., Pohl L.R. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem. Res. Toxicol. 2001, 14:1620-1628.
38. Sato R., Yamaga S., Watanabe K., Hishiyama S., Kawabata K., Kobayashi T., Fujioka D., Saito Y., Yano T., Watanabe K., Watanabe Y., Ishihara H., Kugiyama K. Inhibition of secretory phospholipase A2 activity attenuates lipopolysaccharide-induced acute lung injury in a mouse model. Exp. Lung Res. 2010, 36:191-200.
39. Smith W.L., Rieke C.J., Thuresson E.D., Mulichak A.M., Garavito R.M. Fatty-acid substrate interactions with cyclo-oxygenases. Ernst Schering Res. Found. Workshop. 2000, 31:53-64.
40. Thakore K.N., Mehendale H.M. Role of hepatocellular regeneration in CCl4 autoprotection. Toxicol. Pathol. 1991, 19:47-58.
41. Thakore K.N., Mehendale H.M. Effect of phenobarbital and mirex pretreatments on CCl4 autoprotection. Toxicol. Pathol. 1994, 22:291-299.
42. Whitehouse M.W. Prostanoids as friends, not foes: further evidence from the interference by cycloxygenase-inhibitory drugs when inducing tolerance to experimental arthritigens in rats. Inflammopharmacol. 2005, 12:481-492.
43. Willoughby D.A., Moore A.R., Colville-Nash P.R., Gilroy D. Resolution of inflammation. Int. J. Immunopharmacol. 2000, 22:1131-1135.